Literature DB >> 19808245

Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study.

Juan F Navarro-González1, Carmen Mora-Fernández, Mercedes Muros, Haridian Herrera, Javier García.   

Abstract

BACKGROUND AND OBJECTIVES: Mineral metabolism abnormalities and inflammation are concerns in chronic kidney disease (CKD). Interrelationships among these parameters have not been analyzed. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: The study included 133 patients with CKD not on dialysis and not receiving calcium (Ca) supplements, phosphate binders, or vitamin D. Estimated GFR (eGFR) was 34.1 +/- 6.8 ml/min/1.73 m(2); 107 participants had stage 3 CKD, and 26 had stage 4.
RESULTS: Patients were classified by tertiles of Ca, phosphorus (P), Ca-P product (Ca x P), and parathyroid hormone (PTH). After adjustment for age, gender, and eGFR, the levels of C-reactive protein (CRP) and IL-6 (IL-6) of the third tertile of P, Ca x P, and PTH were significantly higher than those of the first and second tertiles. Serum P and Ca x P directly correlated with CRP and IL-6, whereas HDL-cholesterol and eGFR inversely correlated with the levels of the inflammatory parameters. After partial correlation analysis, the previous associations between CRP and eGFR, and serum P, as well as the relationship between IL-6 and eGFR, and serum P, remained significant. Multiple regression analysis demonstrated that eGFR and serum P were independently associated with CRP and IL-6. Finally, logistic regression analysis using the presence/absence of an inflammatory state as the dependent variable showed that eGFR was a protective factor, whereas serum P was an independent risk factor for the presence of an inflammatory state.
CONCLUSIONS: Elevated serum P might play a role in the development of inflammation in CKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808245      PMCID: PMC2758261          DOI: 10.2215/CJN.02420409

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  55 in total

1.  Linkage of elevated CaxPO4 product with inflammation in maintenance hemodialysis patients.

Authors:  H Nasri
Journal:  Minerva Urol Nefrol       Date:  2006-12       Impact factor: 3.720

Review 2.  Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor?

Authors:  Steven G Achinger; Juan Carlos Ayus
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

3.  Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease.

Authors:  Shifra Sela; Revital Shurtz-Swirski; Meital Cohen-Mazor; Rafi Mazor; Judith Chezar; Galina Shapiro; Kamal Hassan; Galina Shkolnik; Ronit Geron; Batya Kristal
Journal:  J Am Soc Nephrol       Date:  2005-06-29       Impact factor: 10.121

4.  Progression of coronary artery calcification in predialysis patients.

Authors:  Domenico Russo; Salvatore Corrao; Ida Miranda; Carolina Ruocco; Simona Manzi; Rosanna Elefante; Diego Brancaccio; Mario Cozzolino; Maria L Biondi; Vittorio E Andreucci
Journal:  Am J Nephrol       Date:  2007-02-20       Impact factor: 3.754

5.  A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients.

Authors:  Ezio Movilli; Annalisa Feliciani; Corrado Camerini; Giulio Brunori; Roberto Zubani; Francesco Scolari; Giovanni Parrinello; Giovanni C Cancarini
Journal:  Nephron Clin Pract       Date:  2005-08-09

6.  Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease.

Authors:  Vandana Menon; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Santica M Marcovina; Andrew S Levey; Mark J Sarnak
Journal:  Am J Kidney Dis       Date:  2003-07       Impact factor: 8.860

7.  Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.

Authors:  Kazuhiro Yamada; Shouichi Fujimoto; Takeshi Tokura; Keiichi Fukudome; Hideyuki Ochiai; Hiroyuki Komatsu; Yuji Sato; Seiichiro Hara; Tanenao Eto
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

Review 8.  Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences.

Authors:  M I Yilmaz; J J Carrero; J Axelsson; B Lindholm; P Stenvinkel
Journal:  Clin Nephrol       Date:  2007-07       Impact factor: 0.975

9.  Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort.

Authors:  U Baber; J A de Lemos; A Khera; D K McGuire; T Omland; R D Toto; S S Hedayati
Journal:  Kidney Int       Date:  2007-12-12       Impact factor: 10.612

Review 10.  Special characteristics of atherosclerosis in chronic renal failure.

Authors:  K Amann; K Tyralla; M L Gross; T Eifert; M Adamczak; E Ritz
Journal:  Clin Nephrol       Date:  2003-07       Impact factor: 0.975

View more
  32 in total

Review 1.  A narrative review of exosomes in vascular calcification.

Authors:  Zheng Qin; Ruoxi Liao; Yuqin Xiong; Luojia Jiang; Jiameng Li; Liya Wang; Mei Han; Si Sun; Jiwen Geng; Qinbo Yang; Zhuyun Zhang; Yupei Li; Heyue Du; Baihai Su
Journal:  Ann Transl Med       Date:  2021-04

2.  Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.

Authors:  Yu-Ming Chang; Shih-Ching Tsai; Chih-Chung Shiao; Hung-Hsiang Liou; Chuan-Lan Yang; Nai-Yu Tung; Kua-Sui Hsu; I-Ling Chen; Mei-Chyn Liu; Jsun-Liang Kao; Rong-Na Jhen; Ya-Ting Huang
Journal:  Clin Exp Nephrol       Date:  2016-12-07       Impact factor: 2.801

Review 3.  Ironing out the cross talk between FGF23 and inflammation.

Authors:  Valentin David; Connor Francis; Jodie L Babitt
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

Review 4.  Does inflammation affect outcomes in dialysis patients?

Authors:  Kristen L Nowak; Michel Chonchol
Journal:  Semin Dial       Date:  2018-03-07       Impact factor: 3.455

5.  Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease.

Authors:  Jose-Luiz Figueiredo; Masanori Aikawa; Chunyu Zheng; Jacob Aaron; Lilian Lax; Peter Libby; Jose Luiz de Lima Filho; Sabine Gruener; Jürgen Fingerle; Wolfgang Haap; Guido Hartmann; Elena Aikawa
Journal:  Am J Pathol       Date:  2015-02-10       Impact factor: 4.307

6.  Association of chronic kidney disease with muscle deficits in children.

Authors:  Bethany J Foster; Heidi J Kalkwarf; Justine Shults; Babette S Zemel; Rachel J Wetzsteon; Meena Thayu; Debbie L Foerster; Mary B Leonard
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

7.  Fibroblast growth factor 23 and Inflammation in CKD.

Authors:  Jair Munoz Mendoza; Tamara Isakova; Ana C Ricardo; Huiliang Xie; Sankar D Navaneethan; Amanda H Anderson; Lydia A Bazzano; Dawei Xie; Matthias Kretzler; Lisa Nessel; L Lee Hamm; Lavinia Negrea; Mary B Leonard; Dominic Raj; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2012-05-03       Impact factor: 8.237

8.  Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.

Authors:  Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Javier Donate-Correa; Violeta Cazaña-Pérez; Javier García-Pérez
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

Review 9.  Inflammation regulates fibroblast growth factor 23 production.

Authors:  Connor Francis; Valentin David
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 10.  The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know.

Authors:  Orlando M Gutiérrez
Journal:  Adv Nutr       Date:  2013-11-06       Impact factor: 8.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.